297 related articles for article (PubMed ID: 26832214)
21. Stable shRNA Silencing of Lactate Dehydrogenase A (LDHA) in Human MDA-MB-231 Breast Cancer Cells Fails to Alter Lactic Acid Production, Glycolytic Activity, ATP or Survival.
Mack N; Mazzio EA; Bauer D; Flores-Rozas H; Soliman KF
Anticancer Res; 2017 Mar; 37(3):1205-1212. PubMed ID: 28314283
[TBL] [Abstract][Full Text] [Related]
22. Resveratrol suppresses cancer cell glucose uptake by targeting reactive oxygen species-mediated hypoxia-inducible factor-1α activation.
Jung KH; Lee JH; Thien Quach CH; Paik JY; Oh H; Park JW; Lee EJ; Moon SH; Lee KH
J Nucl Med; 2013 Dec; 54(12):2161-7. PubMed ID: 24221993
[TBL] [Abstract][Full Text] [Related]
23. Tumor necrosis factor alpha increases aerobic glycolysis and reduces oxidative metabolism in prostate epithelial cells.
Vaughan RA; Garcia-Smith R; Trujillo KA; Bisoffi M
Prostate; 2013 Oct; 73(14):1538-46. PubMed ID: 23818177
[TBL] [Abstract][Full Text] [Related]
24. Molecular characterization of prostatic small-cell neuroendocrine carcinoma.
Clegg N; Ferguson C; True LD; Arnold H; Moorman A; Quinn JE; Vessella RL; Nelson PS
Prostate; 2003 Apr; 55(1):55-64. PubMed ID: 12640661
[TBL] [Abstract][Full Text] [Related]
25. Cyclin D1 Loss Distinguishes Prostatic Small-Cell Carcinoma from Most Prostatic Adenocarcinomas.
Tsai H; Morais CL; Alshalalfa M; Tan HL; Haddad Z; Hicks J; Gupta N; Epstein JI; Netto GJ; Isaacs WB; Luo J; Mehra R; Vessella RL; Karnes RJ; Schaeffer EM; Davicioni E; De Marzo AM; Lotan TL
Clin Cancer Res; 2015 Dec; 21(24):5619-29. PubMed ID: 26246306
[TBL] [Abstract][Full Text] [Related]
26. Wortmannin influences hypoxia-inducible factor-1 alpha expression and glycolysis in esophageal carcinoma cells.
Zeng L; Zhou HY; Tang NN; Zhang WF; He GJ; Hao B; Feng YD; Zhu H
World J Gastroenterol; 2016 May; 22(20):4868-80. PubMed ID: 27239113
[TBL] [Abstract][Full Text] [Related]
27. Cancer cell metabolism: there is no ROS for the weary.
Dang CV
Cancer Discov; 2012 Apr; 2(4):304-7. PubMed ID: 22576206
[TBL] [Abstract][Full Text] [Related]
28. MAOA-a novel decision maker of apoptosis and autophagy in hormone refractory neuroendocrine prostate cancer cells.
Lin YC; Chang YT; Campbell M; Lin TP; Pan CC; Lee HC; Shih JC; Chang PC
Sci Rep; 2017 Apr; 7():46338. PubMed ID: 28402333
[TBL] [Abstract][Full Text] [Related]
29. IL-17 and insulin/IGF1 enhance adhesion of prostate cancer cells to vascular endothelial cells through CD44-VCAM-1 interaction.
Chen C; Zhang Q; Liu S; Parajuli KR; Qu Y; Mei J; Chen Z; Zhang H; Khismatullin DB; You Z
Prostate; 2015 Jun; 75(8):883-95. PubMed ID: 25683512
[TBL] [Abstract][Full Text] [Related]
30. Macrophage-derived reactive oxygen species suppress miR-328 targeting CD44 in cancer cells and promote redox adaptation.
Ishimoto T; Sugihara H; Watanabe M; Sawayama H; Iwatsuki M; Baba Y; Okabe H; Hidaka K; Yokoyama N; Miyake K; Yoshikawa M; Nagano O; Komohara Y; Takeya M; Saya H; Baba H
Carcinogenesis; 2014 May; 35(5):1003-11. PubMed ID: 24318997
[TBL] [Abstract][Full Text] [Related]
31. The influence of CD44v3-v10 on adhesion, invasion and MMP-14 expression in prostate cancer cells.
Harrison GM; Davies G; Martin TA; Mason MD; Jiang WG
Oncol Rep; 2006 Jan; 15(1):199-206. PubMed ID: 16328056
[TBL] [Abstract][Full Text] [Related]
32. A fluorescence-coupled assay for gamma aminobutyric acid (GABA) reveals metabolic stress-induced modulation of GABA content in neuroendocrine cancer.
Ippolito JE; Piwnica-Worms D
PLoS One; 2014; 9(2):e88667. PubMed ID: 24551133
[TBL] [Abstract][Full Text] [Related]
33. CD44 variant 6 is associated with prostate cancer metastasis and chemo-/radioresistance.
Ni J; Cozzi PJ; Hao JL; Beretov J; Chang L; Duan W; Shigdar S; Delprado WJ; Graham PH; Bucci J; Kearsley JH; Li Y
Prostate; 2014 May; 74(6):602-17. PubMed ID: 24615685
[TBL] [Abstract][Full Text] [Related]
34. Bcl-2 protein expression in lung cancer and close correlation with neuroendocrine differentiation.
Jiang SX; Kameya T; Sato Y; Yanase N; Yoshimura H; Kodama T
Am J Pathol; 1996 Mar; 148(3):837-46. PubMed ID: 8774138
[TBL] [Abstract][Full Text] [Related]
35. AMPK-mediated increase of glycolysis as an adaptive response to oxidative stress in human cells: implication of the cell survival in mitochondrial diseases.
Wu SB; Wei YH
Biochim Biophys Acta; 2012 Feb; 1822(2):233-47. PubMed ID: 22001850
[TBL] [Abstract][Full Text] [Related]
36. [Neuroendocrine differentiation in prostate cancer].
Wu CY; Na YQ; Yao JL; di Sant'Agnese PA; Huang JT
Zhonghua Bing Li Xue Za Zhi; 2006 Sep; 35(9):565-7. PubMed ID: 17134555
[No Abstract] [Full Text] [Related]
37. The prostatic endocrine-paracrine (neuroendocrine) regulatory system and neuroendocrine differentiation in prostatic carcinoma: a review and future directions in basic research.
Di Sant'Agnese PA; Cockett AT
J Urol; 1994 Nov; 152(5 Pt 2):1927-31. PubMed ID: 7933249
[TBL] [Abstract][Full Text] [Related]
38. Aneustat (OMN54) has aerobic glycolysis-inhibitory activity and also immunomodulatory activity as indicated by a first-generation PDX prostate cancer model.
Qu S; Xue H; Dong X; Lin D; Wu R; Nabavi N; Collins CC; Gleave ME; Gout PW; Wang Y
Int J Cancer; 2018 Jul; 143(2):419-429. PubMed ID: 29441566
[TBL] [Abstract][Full Text] [Related]
39. High activity of mitochondrial glycerophosphate dehydrogenase and glycerophosphate-dependent ROS production in prostate cancer cell lines.
Chowdhury SK; Gemin A; Singh G
Biochem Biophys Res Commun; 2005 Aug; 333(4):1139-45. PubMed ID: 15967408
[TBL] [Abstract][Full Text] [Related]
40. Identification of DEK as a potential therapeutic target for neuroendocrine prostate cancer.
Lin D; Dong X; Wang K; Wyatt AW; Crea F; Xue H; Wang Y; Wu R; Bell RH; Haegert A; Brahmbhatt S; Hurtado-Coll A; Gout PW; Fazli L; Gleave ME; Collins CC; Wang Y
Oncotarget; 2015 Jan; 6(3):1806-20. PubMed ID: 25544761
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
